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Background: Calcitriol is documented to cause significant increase in bone mass densitometry counteracting
osteoporosis. Promising results of calcitriol supplementation in studies aiming space flight induced osteoporosis is
little and the effect of this hormone on biomarkers of bone metabolism is not examined yet in space flight models
of osteoporosis in rats.
Methods: This was an interventional animal study being performed in a 1-month period. We included 21 Sprague
Dawley strain rats (>200 gr, >6 week) who were randomly assigned to receive daily supplementation of oral
0.03μgr calcitriol and to be submitted to tail suspension model. Rats were followed for 1 month and were tested
for serum osteocalcin (OC), alkaline phosphatase (ALP) and serum calcium at the beginning and the end of the
study period. The results were analyzed and compared between groups.
Results: Although serum levels of osteocalcin and alkaline phosphatase biomarkers and total serum calcium were
not significantly different within and between study groups, their levels were increased in tail suspension model
compared to control group. The levels of these biomarkers were lower in those who were submitted to tail
suspension model and received calcitriol supplementation compared to those who were only submitted to tail
suspension (60.14 ± 11.73 ng/mL vs. 58.29 ± 2.69 ng/mL; p = 0.696 for osteocalcin and 381.86 ± 99.16 mU/mL vs.
362.57 ± 27.41 ng/mL; p = 0.635 for alkaline phosphatase).
Conclusion: Supplementation of daily diet with calcitriol in rats under weightlessness conditions may results in
lower values for bone metabolic biomarkers of alkaline phosphatase and osteocalcin and serum calcium. This
pattern of change in biomarkers of bone formation, may point to the capacity of calcitriol supplementation in
preventing cellular process of osteoporosis. Thus calcitriol supplementation could be an available, economic and
effective strategy for preventing bone metabolic changes related to weightlessness commonly encountered in
space flight. The outcome of this study needs to be further studied in future trying to find more definite results.
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During space flight, calcium metabolism is directed to-
ward resorption from bone and excretion into urine, all of
which leads to bone loss and renal stone formation [1].
Factors affecting calcium metabolism in these situations
include low dietary intake of calcium, low lighting, in-
creased CO2 levels in the space station environment and* Correspondence: anatomygray2009@gmail.com
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Bone loss and its consequential osteoporosis, is more
exaggerated in the lower extremities of out of space voy-
agers, which point to the unloading as the most important
factor of bone loss [3]. Follow up studies of long duration
space flights including early studies of Mir and Skylab
missions and recent study of NASA bone summit have
shown that bone loss could become up to 15% that was
followed by only 6% of bone recovery after 1 year on earth
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oporosis [6].
Pharmacological interventions to prevent the rate of
bone loss in situations of weightlessness are the focus of
interest in the literature [7,8]. The latest NASA re-
commendation for preventing the rate of bone loss and
hence osteoporosis also included the use of pharma-
cological interventions in the studies designed for such
purposes [5]. Several pharmacologic interventions have
been tested in order to prevent or reverse disuse osteo-
penia. These include the use of antiabsorptive agents like
alendronate and anabolic drugs like estrogen [7]. Sup-
plementation of daily diet with vitamins and elements
acting on bone including vitamin K and D is another
field of interest in preventing disuse osteoporosis [7,8].
These studies demonstrated that vitamin D as contrary
to vitamin K does not show promising results in studies
involving astronauts [8].
One of the disadvantages for designing trial studies
concerning the improvement in bone mineral density is
the rare and expensive settings of trial in out of space or
scarce situations mimicking this condition. Therefore,
the use of animal models for performing studies mimick-
ing weightlessness is becoming more widespread among
researchers [9,10] in recent years, the use of unloaded
rodents as a model of weightlessness that is well known
in the literature as hindlimb suspension model is be-
coming the model of choice for simulating space flight
[11,12]. The influence of different measures for reducing
the detrimental effects of weightlessness on animal bone
has been tested by this model till now. These include the
study of bisphosphonates, testestrone and vitamin K on
bone markers of tail suspended rats [13-15]. The effect
of vitamin D on bone metabolism and bone turn over
markers of out of space voyagers is not demonstrated
yet; therefore in this article the effect of vitamin D on
bone forming biomarkers of hindlimb suspended rats
is studied.
Material and methods
Study animals and grouping
Dawley strain male rats were raised to 6 weeks of age
weighing 220 ± 20 grams at Pastour institute laboratory
and breeding center (Tehran, Iran). At 7 week of age 19
rats were transferred to animal housing and laboratory
affiliated to Iran university of medical sciences (Tehan,
Iran). All rats were housed for 1 week before tail sus-
pension experiment in collective cages with standard
conditions of animal care including that of temperature
(23 ± 2°C) and free access to food and water. They were
randomly assigned into three groups: baseline control
group (n = 7, no intervention, no tail suspension) which
was observed and two subgroups (each n = 7), both were
submitted to tail suspension. The experimental studywas approved by the Ethics Committee on Animal
Research of AJA University of Medical Sciences, with
approval code of 691180 in 31 January 2012.
Study protocol and intervention
One group (n = 5) was housed in conventional CP-3
cages receiving general laboratory care for 1 month dur-
ing the experiment. Two other groups (n = 7, each) were
submitted to modified metabolic cages under hindlimb
unloaded condition through tail suspension for 1 month.
The suspension method was performed Morey-Holton
and Wronski [11,16]. In this technique the rats were
anesthetized (xylazine 30 mg/kg body weight and keta-
mine 30 mg/kg body weight) and traction tape was ap-
plied at the base of the tail. The prepared rats were then
attached to the top part of metabolic cages equipped
with suspension device. This technique of unloading was
previously used successfully in rats and it has become
the method of choice for space flight simulation [11]. It
is also shown that animals gain weight during tail sus-
pension indicating less stressful nature of the technique
in comparison to other methods like back harness [16].
During the suspension period the rats had free access to
food and water and they were kept in standard condi-
tions of laboratory care with 12-h light/dark cycle.
One suspended subgroup (n = 7) was given 4 IU/Kg
calcitriol (1,25 2OH vitamin D3) suspension in daily
water. Calcitriol (an oil soluble drug) was changed into
water suspension drug form by I-Safshekan D-Pharm
(Baabak pharmacy, Shiraz, Iran).
Sampling and measurements
The rats were sampled for their blood in the beginning
and the end of the experiment. Sera from blood samples
were collected and placed in minus 80°C freezer. All
samples are tested at the end of the experiment for
serum calcium and markers of bone formation including
ALP and OC in the Endocrinology and Metabolism
Research Institute, Tehran University of Medical Sciences,
Tehran, Iran. OC was measured using commercially
available rat specific Osteocalcin® laboratory Eliza kit pur-
chased from Hangzhou Eastbiopharm Co., Ltd. (Hangzhou,
China) and the tests were run as recommended by the
manufacturer. Calcium and ALP were measured by spec-
trometry and enzymatic techniques respectively in the
Endocrinology and Metabolism Research Institute affi-
liated to Tehran University of Medical Sciences, Tehran,
Iran.
Statistical analysis
In order to have 90% power to detect significant differen-
ces between changes in biomarkers of bone metabolism, 7
animals were required in each intervention subgroups and
5 rats in the control group. The Statistical Package for
Table 2 Study measurements at the beginning and the







Suspended group and calcitriol
supplementation (n = 7)
Osteocalcin (ng/mL) 59.71 ± 1.79 53.43 ± 7.27 0.05
ALP (mU/mL) 357.86 ± 21.76 370.71 ± 84.02 0.68
Serum calcium (mg/dL) 9.77 ± 0.22 9.61 ± 0.54 0.55
Only suspended group (n = 7)
Osteocalcin (ng/mL) 57.71 ± 2.69 60.14 ± 11.73 0.66
ALP (mU/mL) 344.71 ± 12.459 381.86 ± 99.16 0.31
Serum calcium (mg/dL) 9.82 ± 0.19 9.75 ± 0.42 0.59
Control group (n = 7)
Osteocalcin (ng/mL) 58.14 ± 2.61 58.29 ± 2.69 0.93
ALP (mU/mL) 357.86 ± 26.36 362.57 ± 27.41 0.53
Serum calcium (mg/dL) 9.8 ± 0.23 9.78 ± 0.23 0.85
Values are presented as mean ± SE.
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Chicago, IL) was used for data analysis. Paired t-tests were
used to compare results within groups; independent
t-tests were used to compare results between the groups.
Data are reported as means ± SD. A two-sided p-value less
than 0.05 was considered statistically significant.
Results
A total number of 21 rats were included in the study
that all finished the study period. Three study groups,
out of which two groups were submitted to hindlimb
suspension through tail suspension and one control
group was selected from the same strain and under the
same conditions including that of food and water except
for the calcitriol supplementation of one suspended group.
Table 1 summarizes the main outcomes of the study.
There was no significant difference within and between
all study groups regarding the baseline measurements
for OC and ALP biomarkers (Tables 1 and 2). Those
who received calcitriol and were submitted to hindlimb
suspension during the study had lower values for OC
and ALP at the end of the study compared to the only sus-
pended group (53.43 ± 7.27 ng/mL vs. 60.14 ± 11.73 ng/mL;
p = 0.227 for osteocalcin, 370.71 ± 84.02 mU/mL vs.
381.86 ± 99.16 mU/mL; p = 0.824 for alkaline phosphatase)
and higher values regarding ALP compared to the control
group (370.71 ± 84.02mU/mL vs. 362.57 ± 27.41mU/mL;
p = 0.814) and lower values regarding OC compared to
control group (53.43 ± 7.27 ng/mL vs. 58.29 ± 2.69 ng/mL;
p = 0.138) though the differences were not significant.
The drug supplemented group also had lower serum cal-
cium (9.61 ± 0.54 vs. 9.75 ± 0.42; p = 0.596) compared to
the only suspended group, though the differences were not
significant.
Discussion
During space flight physiologic changes happen in the
bone metabolism in the body of astronauts in response
to microgravity. These include decrease in calcitriol
levels along with increase in serum calcium content
pointing to the release of calcium from bone tissueTable 1 Test results of 20 rats who received tail suspension











53.43 ± 7.27 370.71 ± 84.02 9.61 ± 0.54
Only suspended group
(n = 7)
60.14 ± 11.73 381.86 ± 99.16 9.75 ± 0.42
Control group (n = 7) 58.29 ± 2.69 362.57 ± 27.41 9.78 ± 0.23
Values are presented as mean ± SE. The data were not significant between groups.[8,17]. Furthermore during tail suspension model in ani-
mals, it is documented that serum levels of OC and ALP
also increase in response to unloading [18]. New inter-
ventions are now underway to prevent osteoporosis dur-
ing weightlessness by preventing this process. In this
article we have tested the effect of activated vitamin D
supplementation on serum calcium and biomarkers of
bone formation. Our data though did not become statis-
tically significant are in favor of lower serum values for
OC, ALP and calcium in the tail suspended group re-
ceiving calcitriol supplementation compared to the tail
suspended group alone (Figures 1, 2 and 3). The study
was also in favor of the increased values for OC, ALP
and calcium in tail suspended group alone, all point to
increased bone turnover in this group leading to higher













Osteocalcin (beginning of study)
Osteocalcin (end of study)
Figure 1 Comparison of test value for osteocalcin biomarker at
the beginning and the end of study within and between
















Alkaline psosphatase (beginning 
of study)
Alkaline psosphatase (end of 
study)
Figure 2 Comparison of test value for ALP biomarker at the
beginning and the end of study within and between groups.
(Data were not significant).
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mice [18] (Figures 1, 2 and 3).
Bone metabolism is the result of two opposite mecha-
nisms involved in bone turn over. These include bone
formation and resorption happening continuously as the
tissue evolves [19]. Several markers of bone turnover
each assessing specific physiolocal properties of this
process have been introduced till now [20]. These mar-
kers have been used for assessing different pathologies
related to bone tissue like metabolic bone disorders,
complications of different metastatic diseases involving
bone and risk of fractures and even diseases not invol-
ving bone and skeletal system [21-23]. Successful rela-
tionships are also established between bone markers of
turnover and bone mass densitometry and fracture risk
[24]. One important aspect of using bone turnover
markers is their capacity to detect early bone responses
to treatment regimens [20] while on a molecular point
of view, these markers provide researchers with novel
opportunities to evaluate bone cellular responses to new
interventions [25].
An increased serum level of ALP, a bone formation
marker, is correlated with low BMD scores which points















Calcium (beginning of study)
Calcium (end of study)
Figure 3 Comparison of test value for serum calcium at the
beginning and the end of study within and between groups.
(Data were not significant).loss [26]. This finding has lead to the reinforcement of
endocrine society to conduct studies for finding inter-
ventions capable of reducing this marker [26]. The ad-
ministration of vitamin D in vitamin D deficient patients
is shown to reduce this biomarker [27,28]. On the other
hand increase in ALP is shown to correlate with the im-
provement in bone mass densitometry during treatment
with parathyroid hormone analogues in osteoporosis
[29]. These findings point to ALP, to be a marker of
bone formation and surrogate marker of bone loss, all
together indicating the need for couscous and proper in-
terpretation of the change in this biomarker.
Although vitamin D supplementation is documented
to cause significant increase in bone mass densitometry
and decrease in the risk of bone fracture [30,31], the
effect of this vitamin on OC that is another biomarker
of bone formation is still unclear. Regarding this marker,
it is shown that OC is increased after treatment with
vitamin D, but this change in OC level was repeatedly
reported to be not significant in the literature [32,33].
Furthermore it is demonstrated that unlike vitamin K,
vitamin D does not change undercarboxylated OC ratio
with OC [32]. All of these documents point to the
equivocal response of bone tissue to the administration
of vitamin D supplement.
Weightlessness situations cause decrease in PTH level
which in turn causes decrease in calcitriol level with the
net result for serum calcium content to become de-
pendent on skeletal calcium resorpsion [34]. Although a
rare presentation, hypercalcemia mediated by calcitriol is
reported in specific patients like sarcoidosis and lym-
phoma [35,36], here we have shown decrease in serum
calcium content after administration of calcitiol along
with suppression of bone metabolic markers including
ALP ad OC. This shows hypometabolic state of bone
metabolism and decrease in serum calcium content
similar to the effect of steroid on bone metabolism [37].
Altogether these findings indicate antiresorptive effect of
calcitriol on bone metabolism. The inability of calcitriol
supplementation in increasing the serum calcium con-
tent may be in part explained by lack of calcium supple-
mentation and possible counter absorptive effect of
calcitriol of bone metabolism theorized here.
Our data was consistent with the inhibiting effect of cal-
citriol on bone osteoblastic activity. This was accompanied
by lower values for serum calcium in the calcitriol supple-
mented group, which may point to the simultaneous in-
hibition of osteoclastic activity in this group. Considering
that bone osteoclastic activity that leads to release of cal-
cium from bone tissue is the underlying cause for space
flight induced osteoporosis [17] herein it is hypothesized
that calcitriol suppresses bone turnover thereby prevent-
ing osteoporosis in rat tail suspension model. The inhib-
ition of bone turnover by calcitriol is reflected in lower
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study though they were not statistically significant point-
ing to the need for further studies in future.
We note the following limitations to our study. First,
limited number of rats was included in our study which
may result in low power of the study. Although the sample
size calculation and power assessments demonstrated that
our study has the 90% power to detect the significant
difference the study results did not become significant.
Second, change in ALP and OC levels obey a bimodal
pattern during tail suspension. This pattern was reported
by a study conducted on different strains of mice indi-
cating that although serum levels of ALP and OC in-
crease after 2 weeks of suspension, their values tend to
restore in the next week [18]. This pattern point to the
need for multiple sampling during tail suspension stu-
dies to detect significant differences.
Third, we did not assess other biomarkers of bone
metabolism. This could limit our interpretation of cellu-
lar responses to treatment regimens. However objec-
tively, it is clear that biomarkers of bone formation that
we studied here, account for osteoblastic activity in the
process of bone turn over and their results accompanied
by the measurement of other markers of bone meta-
bolism like vitamin D and calcium would yield to appro-
priate assessment of bone metabolism in the study.
Future studies with larger study populations and meas-
urement of other biomarkers of bone metabolism are
recommended to support the result of our study.
Conclusion
We have studied the biomarkers of bone formation to as-
sess the effect of calcitriol supplementation on bone cellu-
lar responses during weightlessness in rats by means of
tail suspension model that is the model of choice for space
flight simulation in laboratory.
In conclusion, supplementation of daily diet with acti-
vated vitamin D could result in lower levels of OC and
ALP, along with lower levels of serum calcium in hindlimb
suspended rats compared to tail suspension alone in ani-
mal model of weightlessness. This was in favor of inhibit-
ing effect of calcitriol on bone turnover and thereby
inhibiting the process of osteoporosis in tail suspended
rats. Our study possess some limitations including low
number of study groups leading to statistically not signifi-
cant results pointing to the need for future studies to test
the hypothesized role for calcitriol supplementation on
bone metabolism in space flight animal models.
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